Ho-Yeong Lim

2.3k total citations
13 papers, 691 citations indexed

About

Ho-Yeong Lim is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ho-Yeong Lim has authored 13 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ho-Yeong Lim's work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Palliative Care and End-of-Life Issues (4 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). Ho-Yeong Lim is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Palliative Care and End-of-Life Issues (4 papers) and Childhood Cancer Survivors' Quality of Life (3 papers). Ho-Yeong Lim collaborates with scholars based in South Korea, United States and Taiwan. Ho-Yeong Lim's co-authors include Luigi Bolondi, Thierry André, Reiner Wiest, Jordi Bruix, Won Young Tak, Antonio Gasbarrini, Armando Santoro, M. Colombo, Vincenzo Mazzaferro and María Reig and has published in prestigious journals such as Journal of Hepatology, European Journal of Cancer and BMC Cancer.

In The Last Decade

Ho-Yeong Lim

13 papers receiving 674 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ho-Yeong Lim South Korea 11 348 209 149 144 118 13 691
Michael F. Daily United States 17 268 0.8× 244 1.2× 124 0.8× 50 0.3× 112 0.9× 34 947
Olumide B. Gbolahan United States 18 72 0.2× 312 1.5× 59 0.4× 70 0.5× 68 0.6× 65 766
Lois Dickie United States 11 195 0.6× 234 1.1× 48 0.3× 20 0.1× 204 1.7× 14 630
Cindy Lim Singapore 15 90 0.3× 167 0.8× 80 0.5× 47 0.3× 56 0.5× 36 560
Barbara Benton United Kingdom 6 206 0.6× 157 0.8× 25 0.2× 36 0.3× 128 1.1× 10 620
Fausto Meriggi Italy 14 49 0.1× 415 2.0× 92 0.6× 47 0.3× 60 0.5× 63 641
Leïla Bengrine-Lefèvre France 15 92 0.3× 573 2.7× 64 0.4× 24 0.2× 121 1.0× 45 806
Catia Angiolini Italy 11 217 0.6× 280 1.3× 48 0.3× 24 0.2× 116 1.0× 20 570
Neeta K. Venepalli United States 11 148 0.4× 84 0.4× 33 0.2× 20 0.1× 75 0.6× 33 434
Janine M. Davies Canada 11 64 0.2× 209 1.0× 89 0.6× 28 0.2× 38 0.3× 42 377

Countries citing papers authored by Ho-Yeong Lim

Since Specialization
Citations

This map shows the geographic impact of Ho-Yeong Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ho-Yeong Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ho-Yeong Lim more than expected).

Fields of papers citing papers by Ho-Yeong Lim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ho-Yeong Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ho-Yeong Lim. The network helps show where Ho-Yeong Lim may publish in the future.

Co-authorship network of co-authors of Ho-Yeong Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Ho-Yeong Lim. A scholar is included among the top collaborators of Ho-Yeong Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ho-Yeong Lim. Ho-Yeong Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Ryoo, Baek‐Yeol, Philippe Merle, Joong‐Won Park, et al.. (2020). Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 5(4). e000714–e000714. 61 indexed citations
3.
Lencioni, Riccardo, Robert Montal, Ferràn Torres, et al.. (2017). Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology. 66(6). 1166–1172. 153 indexed citations
4.
Bruix, Jordi, Won Young Tak, Antonio Gasbarrini, et al.. (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European Journal of Cancer. 49(16). 3412–3419. 203 indexed citations
5.
Choi, Jin Young, Dae Seog Heo, Samyong Kim, et al.. (2012). Complementary and Alternative Medicine Use among Cancer Patients at the End of Life: Korean National Study. Asian Pacific Journal of Cancer Prevention. 13(4). 1419–1424. 20 indexed citations
6.
Yoon, Won Sup, Won Park, Doo Ho Choi, et al.. (2011). Which Patients Benefit from Preoperative Chemoradiotherapy for Intermediate Staged Rectal Cancer?. Onkologie. 34(1-2). 36–41. 2 indexed citations
7.
Yeo, Winnie, Pei‐Jer Chen, Junji Furuse, et al.. (2010). Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. BMC Cancer. 10(1). 620–620. 4 indexed citations
8.
Chen, Pei‐Jer, Junji Furuse, Kwang‐Hyub Han, et al.. (2010). Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver International. 30(10). 1427–1438. 34 indexed citations
9.
Park, Sang Min, Young Jin Kim, Samyong Kim, et al.. (2009). Impact of caregivers’ unmet needs for supportive care on quality of terminal cancer care delivered and caregiver’s workforce performance. Supportive Care in Cancer. 18(6). 699–706. 69 indexed citations
10.
Yun, Young Ho, Myung Kyung Lee, Yoon Jung Chang, et al.. (2009). The life-sustaining treatments among cancer patients at end of life and the caregiver’s experience and perspectives. Supportive Care in Cancer. 18(2). 189–196. 33 indexed citations
11.
Park, Joon Oh, Yong‐Seok Jee, Dong Wook Choi, et al.. (2007). A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 60(4). 489–494. 16 indexed citations
12.
Yun, Young Ho, Sang Min Park, Samyong Kim, et al.. (2007). Chemotherapy Use and Associated Factors among Cancer Patients near the End of Life. Oncology. 72(3-4). 164–171. 59 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael F. Daily Breakdown of academic impact, for papers by Olumide B. Gbolahan Breakdown of academic impact, for papers by Lois Dickie Breakdown of academic impact, for papers by Cindy Lim Breakdown of academic impact, for papers by Barbara Benton Breakdown of academic impact, for papers by Fausto Meriggi Breakdown of academic impact, for papers by Leïla Bengrine-Lefèvre Breakdown of academic impact, for papers by Catia Angiolini Breakdown of academic impact, for papers by Neeta K. Venepalli Breakdown of academic impact, for papers by Janine M. Davies
Rankless by CCL
2026